Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehrdad Abedi

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Blood|August 23, 2021
Increased efficacy of dual proinflammatory cytokine blockade on acute GVHD while maintaining GVT effectsLam T Khuat, Logan V Vick, Cordelia Dunai, et al.
Blood Advances|February 24, 2026
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Blood Advances|November 10, 2025
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative AnalysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Scientific Reports|October 16, 2024
Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell diseaseSamuel Lessard, Pauline Rimmelé, Hui Ling, et al.
Ejhaem|July 18, 2022
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect<sup>®</sup> MDS/AML Disease RegistryDaniel A Pollyea, Tracy I George, Mehrdad Abedi, et al.
International Journal of Laboratory Hematology|November 21, 2020
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromesJay L Patel, Mehrdad Abedi, Christopher R Cogle, et al.
Transplantation and Cellular Therapy|April 22, 2023
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to CareBenjamin Tomlinson, Marcos de Lima, Christopher R Cogle, et al.
Journal for Immunotherapy of Cancer|August 30, 2023
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Blood|April 7, 2021
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 resultsBijal D Shah, Michael R Bishop, Olalekan O Oluwole, et al.
Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Blood|August 23, 2021
Increased efficacy of dual proinflammatory cytokine blockade on acute GVHD while maintaining GVT effectsLam T Khuat, Logan V Vick, Cordelia Dunai, et al.
Blood Advances|February 24, 2026
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Blood Advances|November 10, 2025
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative AnalysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Scientific Reports|October 16, 2024
Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell diseaseSamuel Lessard, Pauline Rimmelé, Hui Ling, et al.
Ejhaem|July 18, 2022
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect<sup>®</sup> MDS/AML Disease RegistryDaniel A Pollyea, Tracy I George, Mehrdad Abedi, et al.
International Journal of Laboratory Hematology|November 21, 2020
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromesJay L Patel, Mehrdad Abedi, Christopher R Cogle, et al.
Transplantation and Cellular Therapy|April 22, 2023
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to CareBenjamin Tomlinson, Marcos de Lima, Christopher R Cogle, et al.
Journal for Immunotherapy of Cancer|August 30, 2023
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Blood|April 7, 2021
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 resultsBijal D Shah, Michael R Bishop, Olalekan O Oluwole, et al.
Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Pageof 7